Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/1b Study of T-allo10 Infusion After αβ Depleted-HSCT in Hematologic Malignancies
NCT04640987Phase 1Recruiting
- Start
- Feb 2021
- Primary completion
- Mar 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of T-allo10 in hematologic malignancy (3 cohorts). Primary endpoints: Recommended Phase 2 Dose, Dose-Limiting Toxicity and 1 more. Started Feb 2021; status: recruiting.
02
Drugs
T-allo10
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT04640987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640987.